Introduction
Mature blood cells originate from a population of selfrenewing stem cells which are believed to be in a noncycling state under steady-state conditions (Ogawa, 1993; Sie, 1994; Orkin, 1995) . In response to a demand by the body for mature blood cells, the stem cells generate a group of progenitor cell populations that express speci®c cytokine receptors on their surface and proliferate or dierentiate in response to cognate cytokine binding (Ogawa, 1993; Sie, 1994; Orkin, 1995) . Interleukin-3 is unique among the hematopoietic growth factors in its broad spectrum of activity on multiple lineages, and this has been attributed to its ability to support the growth of pluripotent hematopoietic progenitors (Cotter et al., 1994) . Studies with hematopoietic cell lines grown in culture have shown that IL-3 plays an essential role in the survival and proliferation of hematopoietic precursor cells, and current evidence suggests that this is accomplished by the suppression of an endogenous suicide mechanism termed apoptosis (Cotter et al., 1994; Bay et al., 1993) . Apoptosis, or programmed cell death, is a process where developmental or environmental stimuli activate a genetic program to implement a series of events that culminate in cell death (White, 1995; Cotter et al., 1994; Homan and Liebermann, 1994) . In lower eukaryotes distinct genetic loci regulate the ability of cells to undergo apoptosis during development (Stellar, 1995; Yuan, 1996) , but little is known about genes that in¯uence this process during hematopoiesis. Their identi®cation may provide important insights into the regulation of hematopoiesis, and into novel pathways of transformation which render a cell unresponsive to physiological signals to self-destruct.
To study the nature of genes that are induced during the apoptotic death of myeloid precursor cells, we utilized the 32Dcl3 cell line, which is derived from normal mouse bone marrow, is non-tumorigenic and diploid. These cells are strictly dependent on IL-3 for growth and apoptose when deprived of IL-3 (Greenberger, 1983; Rovera et al., 1987; Valtieri et al., 1987) . However, when these cells are transferred to medium containing G-CSF, the cell number increases 4 ± 5-fold and after 12 days the entire population is dierentiated into morphologically normal and myeloperoxidase positive metamyelocytes and granulocytes Valtieri et al., 1987) . In our search for genes that are induced during terminal dierentiation of 32Dcl3 cells, we identi®ed a novel gene termed AATYK (Apoptosis Associated Tyrosine Kinase), whose expression is dramatically upregulated during IL-3 deprivation as well as G-CSF-induced terminal dierentiation of these cells. In this report, we describe the sequence of the cDNA clone, derived from the mRNA transcript of this gene. These studies show that this gene encodes a protein with a tyrosine kinase domain at the N-terminal end and a proline-rich domain at the C-terminal end. We also report that the expression of this gene is blocked in v-abl or bcr ± abl transformed myeloid cells which are unable to apoptose when deprived of IL-3.
Results

Identi®cation and molecular cloning of AATYK
It is now known that cytokines such as G-CSF and GM-CSF induce proliferation and dierentiation in the same cell, such as 32Dcl3 Valtieri et al., 1987; Krishnaraju et al., 1995) . Subtractive hybridization techniques have in the past successfully been used to identify novel genes that are speci®cally induced during cytokine induced dierentiation of myeloid precursor cells (Abdollahi et al., 1991) . Further analysis of these genes revealed that several of them function as regulators of apoptosis (Homan and Liebermann, 1994) . We utilized the 32Dcl3 cell system to isolate mRNAs at dierent stages of granulocytic dierentiation following exposure to G-CSF. Screening of cDNA libraries prepared from mRNAs extracted from cells at the terminal stages of dierentiation resulted in the identi®cation of a novel cDNA which hybridized to a transcript of approximately 5.5 kb. The restriction map, nucleotide sequence and the putative amino acid sequence encoded by the longest insert representing this novel clone (termed AATYK) are shown in Figures 1, 2 and 3. An examination of this sequence revealed that this cDNA contained an initiator codon at position 106 ± 108 and a terminator codon at position 4057 ± 4059. We could not detect an in-frame terminator codon upstream of the ATG codon, leaving open the possibility that this cDNA may not contain the complete coding sequence of the transcript. To determine whether the mRNA transcript encoded by AATYK contains additional coding sequences and an alternative ATG upstream of position 106 ± 108, we performed two sets of experiments. First, we re-screened our cDNA libraries with a probe derived from the 5' end of the cDNA clone and obtained four additional positive clones. Sequence analysis of these cDNAs did not reveal any additional stretch of coding sequences upstream of the cDNA clone shown in Figure 2 . Second, we performed the RACE (`rapid ampli®cation of cDNA ends') procedure (Lung and Chan, 1996) , which did not reveal the presence of an upstream ATG. Based on these results, and the fact that the size of the cDNA is in very close proximity to the observed size of the mRNA transcript seen in 32D cells, we concluded that the cDNA sequence shown in Figure 1 could contain the entire reading frame of the AATYK gene. This conclusion was further con®rmed by a comparison of the size of the protein encoded by the cDNA with the in vivo form of this protein seen in tissue extracts (see in vitro and in vivo transcription-translation section).
The open reading frame, shown in Figure 2 consists of 3948 bases which could code for a protein of 1316 amino acids of approximately 145 kD. The putative structure of the encoded protein is shown in Figure 3 . The protein encoded by AATYK exhibits extensive homology to tyrosine kinases (Hanks and Hunter, 1995) at the N-terminal end, which spans between amino acid residues 69 ± 350. Computer analysis of this domain shows that it contains a perfect ATP binding domain which extends between amino acid residues 78 and 114, with a glycine rich stretch of residues in the vicinity of a lysine residue which has been shown to be involved in ATP binding (Hanks and Hunter, 1995) . A DLALRN motif, which has been shown to be conserved in the sub-domain of non-Src tyrosine kinases, has also been found in this sequence at position 206 ± 211. The almost invariant motif, DFG, which is usually located in the sub-domain VII of tyrosine kinases, appears to be substituted by the motif DYG at residues 224 ± 226. Recent studies have shown that a few other active kinases have a similar substitution in the DFG motif (Hanks and Hunter, 1995) . AATYK does not appear to contain any SH2 or SH3 domains, but the C-terminal domain was found to be very rich in proline residues. This proline-rich domain was found to contain 16 PXXP motifs, which constitutes the most conserved motif within known SH3 domain ligands (Cohen et al., 1995) , suggesting that AATYK might form signaling complexes with other molecules that contain SH3 domains. These putative binding sites are underlined in Figure 3 . The existence of these domains and the tyrosine kinase domain suggest that AATYK could function as a signal transducing protein. In addition, the protein sequence showed the presence of a CXXC motif at position 504 ± 507, characteristic of the thioredoxin (Trx) family of proteins which play a critical role in the formation of native disul®de bonds in the cell (Chivers et al., 1996) .
AATYK RNA is upregulated during G-CSF-induced terminal dierentiation of 32Dcl3 cells
To examine the role of AATYK in myeloid cell growth and dierentiation, we used the 32Dcl3 cell Figure 1 cDNA restriction map and schematic representation of the murine AATYK protein structure. Important structural features include the tyrosine kinase domain (shaded box), PXXP motifs (black lines) and CXXC motif (hatched box) line which was incubated in G-CSF-containing medium for various periods of time. Under these conditions, this cell line underwent programmed terminal dierentiation along the granulocytic pathway resulting in the accumulation of morphologically normal and myeloperoxidase and lactoferrin positive metamyelocytes and granulocytes after a period of 10 days (Figure 4a ). Northern blot analysis of RNA extracted from these cells incubated in G-CSF for 0, 1, 3, 5, 7 and 9 days is shown in Figure 4b . These results show that the AATYK probe hybridizes to a transcript of 5.5 kb which is not expressed in 32Dcl3 cells growing in the presence of IL-3. However, gradual accumulation of this transcript was seen in these cells as a function of terminal dierentiation, where its levels reached a peak by day 7 and remained relatively stable until the entire population of cells had dierentiated into metamyelocytes and granulocytes. These results suggest that the AATYK transcript is up-regulated during G-CSF-induced terminal differentiation of myeloid precursor cells. 
AATYK expression is upregulated during apoptotic death of 32Dcl3 cells deprived of cytokines in the culture medium
Because G-CSF-induced terminal dierentiation of 32Dcl3 cells is also linked to their apoptotic death, it was of interest to examine the synthesis of AATYK following cytokine deprivation from the 32D cell culture medium since this treatment has been found to induce rapid apoptosis of these cells (Nunez et al., 1990; Askew et al., 1991) . Figure 5a shows the decrease in viability of 32Dcl3 cells grown in the absence of any cytokines, but in the presence of IMDM containing 10% fetal bovine serum. In the absence of IL-3 or G-CSF, these cells gradually lost viability, and by 48 h, approximately 75% of the cells were dead as measured by trypan blue exclusion. The apoptotic nature of their death could be veri®ed by monitoring the electrophoretic mobility of low molecular weight cellular DNA, which showed a characteristic DNA ladder formation ( Figure 5b ). Northern blot analysis of RNA ( Figure 5c ) extracted from 32Dcl3 cells incubated for 4, 8, 16, 24 and 48 h in the absence of IL-3 revealed that AATYK expression is induced in 32Dcl3 cells within 4 h following the removal of IL-3 from the medium and its expression levels reached a maximum at the 48 h time point when more that 75% of the cells were dead. These results demonstrate that AATYK is speci®cally induced during the apoptotic death of 32Dcl3 cells and might act either as a positive or negative regulator of apoptosis in these cells.
AATYK expression in response to IL-3 deprivation is blocked in 32D/v-abl and 32D/bcr ± abl cells
Because several oncogenes such as v-abl or bcl ± abl have been shown to abrogate IL-3-dependence of myeloid precursor cells by subverting apoptotic pathways Laneuville et al., 1991) , it was of interest to see if AATYK expression is blocked by these oncogenes. In addition, it has been recently demonstrated that incubation of 32Dcl3 cells transformed by the v-abl oncogene in the presence of DMSO results in a block in proliferation followed by apoptosis (Zhu et al., 1996) . These studies also revealed that 32Dcl3 cells transformed by bcr ± abl were resistant to the eects of DMSO as they failed to undergo apoptosis. To study if DMSO-mediated apoptosis of 32D/v-abl and 32D/bcr ± abl cells is associated with the induction of AATYK transcription, these cells were grown in medium without DMSO or in medium containing 1.5% DMSO for 1, 3 or 5 days and total RNA was isolated from these cells at these time RNA was isolated at intervals of 0, 1, 3, 5, 7 and 9 days and analysed by Northern blot analysis using the full length cDNA as a probe. The same blot was stripped and hybridized using a G3PDH probe. The top panel shows hybridization with the AATYK probe and the bottom panel shows hybridization with the G3PDH probe points. Cell viability determination revealed that cells incubated in the presence of DMSO enter the apoptotic pathway between 48 and 72 h, while untreated cells fail to do so (Figure 6a ). Northern blot analysis of RNAs extracted from cells grown in the presence of DMSO using an AATYK probe revealed that while AATYK is not expressed in 32D/v-abl cells (lane 1, Figure 6b ), its expression is induced between 48 and 72 h following the addition of DMSO (Figure 6b ), a period when the cells begin to enter the apoptotic pathway as judged by their viability (Figure 6b ) and DNA fragmentation analysis (data not shown). The levels of AATYK RNA expressed in these cells is comparable to the levels of AATYK mRNA induced in normal 32Dcl3 cells that have been induced to apoptose in the absence of IL-3 for 24 h (lane 5 of Figure 6b ). We next performed an identical experiment with 32D/bcr ± abl cells, which are known to be resistant to DMSO-induced apoptosis (Zhu et al., 1997;  Figure 6c ). These cells failed to express detectable levels of AATYK even after incubation of these cells for 5 days in 1.5% DMSO (Figure 6d, lanes 1 ± 4) . As a positive control for these experiments, the gel was loaded with 20 mg of total RNA extracted from 32Dcl3 cells incubated for 24 h in the absence of IL-3 (lane 5). This RNA, as expected, hybridized with the AATYK probe with high intensity. These results, taken together, suggest that AATYK gene expression is associated with induction of growth arrest and/or apoptosis, and that oncogenes such as v-abl and bcr ± abl which override the apoptotic pathways in myeloid precursor cells block the synthesis of AATYK However, when these cells are treated with agents that can induce growth arrest and apoptosis, the expression of AATYK is restored concomitant to the induction of the growth arrest and apoptotic pathways.
Tissue expression of AATYK
To determine if AATYK is expressed in tissues other than myeloid cells, we probed a multiple tissue Northern blot (Clontech) with the full length AATYK cDNA clone. This result, shown in Figure 7 , demonstrates that the AATYK gene is expressed at low levels in most tissues such as the kidney, heart, lung, and skeletal muscle and at the highest level in the brain. In these tissues, the message appears as a 5.1 and 5.5 kb doublet, suggesting that AATYK may exist in an alternatively spliced form. Interestingly, the AATYK probe also hybridized almost exclusively to smaller transcripts of 2.0 and 2.5 kb in the liver and, to a much lesser extent, skeletal muscle. It is therefore possible that this gene encodes more than one protein species and that the nature of a particular protein species may be tissue-speci®c.
In vitro and in vivo transcription-translation of AATYK Because we were unable to detect an in-frame terminator codon which is located upstream of the ®rst ATG, the , 24 and 48 h and was subjected to Northern blot analysis using the full length cDNA as a probe. 28s ribosomal RNA was used as a control for RNA loading. (rRNA was used because G3PDH mRNA was found to degrade rapidly during the death of 32Dcl3 cells) possibility exists that the cDNA sequence presented in Figure 2 may not encode the full length AATYK protein.
To conclusively demonstrate that the cDNA encodes the full length protein, we cloned the full length cDNA into the pCDNA3 (Invitrogen) eukaryotic expression vector (termed pCDNA3-AATYK) and used this plasmid as a template for T7-primed TNT (Promega) coupled in vitro transcription and translation. The major translation product, when analysed by SDS ± PAGE, migrated as a 200 kD band (Figure 8a ). We next generated a 32Dcl3 cell line using the LacSwitch system (Stratagene) which expresses AATYK under the control of an IPTGinducible promoter (Stratagene). The results of this experiment, shown in Figure 8b , show that 32Dcl3 cells which have been transfected with the parental vector and are maintained in IL-3 do not express detectable levels of AATYK in the absence or presence of inducer (lanes 1 ± 3). Similarly, 32Dcl3 cells which have been transfected with an inducible AATYK expression plasmid express AATYK at a very low or undetectable levels (lanes 4 and 5) when grown in the presence of IL-3 and in the absence of inducer. However, 32Dcl3/AATYK cells, when grown in the presence of IPTG for 24 h, express a 200 kD protein which is cross-reactive with our AATYK-speci®c antiserum (lane 6). As the brain cells express the highest levels of AATYK RNA and protein, we compared the nature and size of the protein encoded by this cDNA with that expressed in mouse brain using Western blot analysis. The results of this experiment presented in Figure 8a and b show that the protein encoded by the cDNA, when expressed in vitro and in vivo, migrates as a 200 kD band. In addition, the protein encoded by the cDNA clone and that which is present in the brain migrate at approximately the same position on an SDS polyacrylamide gel. Because the size of the cDNA indicates that the AATYK gene should encode a protein of approximately 145 kD, it is possible that AATYK undergoes one or more forms of post-translational modi®cations. An alternative explanation for the dierence in the expected size of the protein and that which is observed lies in the fact that AATYK is rich in proline residues which constitute putative SH3-binding motifs. Other studies (Ishino et al., 1995) have demonstrated that proteins which are proline-rich frequently migrate slower than expected in SDS ± PAGE. Nevertheless, the protein studies presented here further substantiate our conclusion that the cDNA might encode the entire AATYK coding sequence.
Discussion
In this report, we describe the nucleotide sequence of a novel gene which encodes a putative tyrosine kinase that is upregulated during the apoptotic death of myeloid cells. The structure of this protein, which we have termed AATYK (apoptosis associated tyrosine kinase), has several notable features which implicate it in the execution of signal transduction pathways that regulate growth arrest and/or programmed cell death. A putative tyrosine kinase domain, located at the Nterminus of the protein (amino acid residues 59 ± 350), contains a well conserved ATP binding domain, a DLALRN motif which is conserved among non-src family tyrosine kinases and a DYG motif that has been identi®ed in a sub-domain VII of other members of the tyrosine kinase family (Hanks and Quinn, 1991; Hanks et al., 1988; Hanks and Hunter, 1995) . The presence of these conserved residues within AATYK suggests that it may be catalytically active and be able to undergo auto-phosphorylation as well as phosphorylate one or more substrates. However, because AATYK does not possess any SH3 or SH2 domains which are known to mediate binding to other adaptor proteins, substrate recognition and the regulation of enzymatic activity (Koch et al., 1991; Schlessinger, 1994) , it is possible that its functions are regulated in a manner which is distinct from other family members. A distinguishing feature of the amino acid sequence of AATYK is that it has several PXXP motifs which consistute the minimal binding site for other SH3 domain-containing proteins, such as Abl, Crk and Grb2 (Cohen et al., 1995) . Many proteins, including Grb2, function as adaptor molecules which bring other proteins into close proximity of each other so that they can bind to substrates or become part of a larger, more intricate signaling complex (Koch et al., 1991; Schlessing, 1994) . It is therefore feasible that AATYK could recognize its substrate(s) through one or more of its PXXP motifs. Based on this assumption, one could propose a model for the mechanism of action of AATYK, where it binds to other signaling molecules that contain SH3 domain and sequesters them from an active process of signal transduction or inactivates them by phosphorylation on a tyrosine residue. For example, it can be envisaged that AATYK binds to c-Src via its SH3 and inactivates this protein by phosphorylation of Tyr 527, which negatively regulates c-Src (Cooper et al., 1986; Cooper and Howell, 1993) .
The signal transduction pathways in which AATYK function has been implicated thus far include those which regulate the growth, differentiation and apoptosis of myeloid cells. In the 32Dcl3 model system, the AATYK message is undetectable in myeloid precursor cells that are actively proliferating in the presence of IL-3. However, removal of IL-3 from the culture medium results in an induction of the AATYK message within 4 h. This rapid upregulation suggests that AATYK could be an early response gene in myeloid cells that are apoptosing in the absence of survival factors, such as IL-3, which promote both proliferation and cell survival. In addition, AATYK mRNA levels were induced in 32Dcl3 cells undergoing G-CSF induced terminal dierentiation. Because it has been hypothesized that exposure to cytokines such as G-CSF merely delays the onset and duration of the apoptotic response (Cotter et al., 1994) , it remains to be determined whether AATYK functions as a regulator of granulocytic dierentiation or whether its primary function is to govern growth arrest and programmed cell death which follows this process. Our experiments with the 32D/bcr ± abl and 32D/vabl cell lines, however, support the latter notion that AATYK is a potential regulator of the apoptotic response and/or growth arrest. The bcr ± abl and v-abl oncogenes inhibit 32Dcl3 dierentiation in response to G-CSF and block the expression of AATYK even though these transformed cell lines are capable of growing in the absence of IL-3 Laneuville et al., 1991) . It has been recently demonstrated that 32D/v-abl cells, when cultured in the presence of DMSO, enter the phase of growth arrest and subsequently undergo programmed cell death (Zhu et al., 1997) . 32D/bcr ± abl cells, on the other hand, retain their proliferative ability when exposed to DMSO and do not apoptose (Zhu et al., 1997) . The fact that AATYK expression is restored in DMSO-treated 32D/v-abl cells that have growtharrested and are undergoing apoptosis further suggests that its expression is associated with these two inter-dependent pathways.
AATYK is also expressed in several tissues, including the brain, heart, skeletal muscle, kidney and liver; in all tissues, with the exception of the liver, the AATYK message appears as a 5.1 ± 5.5 kb doublet. The liver, and to a much lesser extent, skeletal muscle, express a smaller 2.0 ± 2.5 kb transcript, suggesting that this message is alternatively spliced in a tissue-speci®c manner. If the splicing results in the absence of one or more of the PXXP SH3 ligand binding motifs, or in the modulation of AATYK catalytic activity, it is possible that this may constitute an additional mechanism by which this protein is regulated. Several of the genes involved in the regulation of apoptosis often encode multiple proteins, some of which promote apoptosis, and other which block this process (Reed, 1997) . A good example is seen with the Bcl-X gene which codes for two proteins, termed as Bcl-X L and Bcl-X S . Of these, the larger Bcl-X L protein has been shown to block apoptosis, while the shorter Bcl-X S protein, has been found to promote this process (Boise et al., 1993; Reed, 1997) . This type of regulation may be particularly relevant when viewed in the context of the developing brain. Because a large percentage of neurons die by apoptosis before an organism reaches adulthood (Gordon, 1995; Narayanan, 1997) , AA-TYK may regulate this process by either inducing the apoptosis of those neurons that are programmed to die or by preventing the apoptosis of those which have been instructed to live. Future experiments with 32Dcl3, 32D/bcr ± abl, 32D/v-abl and neuronal cells which constitutively express AATYK in both the sense and anti-sense orientations will undoubtedly shed light onto the function(s) and mechanism of action of this gene. Such an understanding is likely to provide us with an insight into the mechanisms by which transforming oncogenes subvert cellular processes associated with normal growth and apoptosis.
Materials and methods
Cell culture 32Dcl3 cells were maintained in Iscoves Modi®ed Dulbecco's Medium (IMDM) (Life Technologies) supplemented with 10% fetal bovine serum, penicillin-streptomycin (complete medium) and 10% conditioned medium from the WEHI-3 cell lines as a source of IL-3 (Ymer et al., 1985) . For G-CSF induced dierentiation, actively growing cells were washed twice in the above medium (in the absence of IL-3) and plated at 2610 5 cells/ml in complete medium supplemented with 10% conditioned medium from a CHO/GCSF cell line which secretes G-CSF (Rovera et al., 1989; Kreider et al., 1990) . IL-3 withdrawal studies were performed by washing the cells as above and plating them in complete medium in the absence of growth factors. 32D/bcr ± abl and 32D/v-abl cells Zhu et al., 1997) were also maintained in Iscoves Modi®ed Dulbecco's Medium (IMDM) supplemented with 10% fetal bovine serum and penicillin-streptomycin. Cells treated with DMSO were washed twice in the above medium and plated in complete medium at 4610 5 cells/ml in the presence of 1.5% DMSO (Sigma) as described earlier (Zhu et al., 1997) .
Isolation of low molecular weight apoptotic DNA 1610 7 cells were washed once in PBS, resuspended in isotonic buer (100 mM NaCl/1.5 mM MgCl 2 /10 mM TrisCl, pH 7.5/0.15% NP-40/1 mM PMSF) and incubated on ice for 5 min. Samples were centrifuged and the nuclear pellet resuspended in hypotonic lysis solution (5 mM TrisCl, pH 7.5/5 mM EDTA/0.5% Triton X-100/1 mM PMSF). Low molecular weight DNA was isolated by centrifugation and the supernatant extracted once with phenol/chloroform and ethanol precipitated. Samples were resuspended in water, RNAse treated and the DNA heated at 658C for 5 min before loading on a 1.8% agarose gel.
RNA preparation, Northern blot analysis and c-DNA library construction
Total RNA was prepared from all cell lines as previously described (Chomczynski and Sacchi, 1987) . 20 mg of each sample were electrophoresed on a 1% formaldehyde gel and transferred to nytran membranes (Schleicher & Scheull) for Northern blot analysis. Hybridization was performed overnight and washed as previously described (Mettus et al., 1994) . The tissue distribution of AATYK was determined by probing a mouse multiple tissue Northern blot (Clontech) under high stringency conditions according to the instructions of the manufacturer. For the preparation of cDNA libraries, total RNA was fractionated on an oligo dTcellulose column and the poly(A) + RNA was used for the preparation of cDNA libraries from 32Dcl3 cells growing in the presence of IL-3 and cells cultured in the presence of G-CSF for 5 days as previously described (Rane and Reddy, 1994) .
Generation of an AATYK-speci®c antibody
A fragment of DNA encoding amino acid residues 1262 ± 1318 of the AATYK protein was generated by PCR and sub-cloned into the BamHI and EcoRI sites of the pGEX-2T vector (Pharmacia) to generate a GST-AATYK fusion protein. Large scale puri®cation was performed according to the instructions of the manufacturer and the puri®ed protein used as an antigen to generate a rabbit polyclonal antiserum.
In vitro transcription-translation and in vivo analysis of AATYK protein
In vitro transcription-translation was performed using the T7 (to transcribe the sense strand) or SP6 (to transcribe the anti-sense strand) coupled TNT kit (Promega) supplemented with [
35 S]Express Protein Labeling Mixture (NEN, DuPont) as described by the manufacturer. Template DNA (pCDNA3-AATYK) was generated by cloning the full length cDNA into the BamHI and EcoRV sites of the pCNDA3 vector (Invitrogen) in which the neomycin gene has been replaced with that encoding the hygromycin resistance gene. Labeled translation products were analysed on 6% SDS ± PAGE according to Lammeli (1970) and the resulting gel ®xed, enhanced, dried and subjected to autoradiography.
Generation of 32D/AATYK cells
AATYK inducible 32Dcl3 cells were generated using the LacSwitch system (Stratagene). The full length AATYK cDNA was sub-cloned into the pOPRSVI expression vector to generate pOPRSVI-AATYK. 10 mg of linearized expression plasmid and 10 mg of linearized p3'SS repressor plasmid were simultaneously introduced into 32Dcl3 cells by electroporation at 300 volts and a resistance of 960 mFaradays. Transfected cells were selected in 2 mg/ml hygromycin (Calbiochem) and 1 mg/ml G418 (Life Technologies).
Western blot analysis
Whole cell lysates were derived from 32D/AATYK and control vector cells using RIPA buer (150 mM NaCl/ 50 mM Tris-Cl, pH 7.5/1% NP40/0.1% sodium deoxycholate/0.1% SDS/1 mM EDTA/1 mM EGTA/1 mM PMSF/ 4 mg aprotinin/4 mg/ml pepstatin A/4 mg leupeptin). Normal mouse brain whole cell lysates were prepared as previously described (Toscani et al., 1997) . For Western blot analysis, 100 mg of whole cell lysate were separated by SDS ± PAGE (6%) and transferred to a nitrocellulose membrane and probed with an AATYK-speci®c polyclonal antiserum. Proteins were visualized using Enhanced Chemiluminescence (Amersham).
